In the Special Report, “Terms and Conditions: Semantic Complexity and Aspirin Resistance,” by Hennekens et al, which published in the September 21, 2004, issue of the journal (Circulation. 2004;110:1706–1708), the disclosure information was incomplete. Dr Hennekens’ information was included in the article; however, disclosure information for Drs Schror, Weisman, and FitzGerald was reported but not published with the article. We regret this error and include the complete disclosure below.
Dr Hennekens is funded by the Department of Biomedical Science and The Center of Excellence at Florida Atlantic University (FAU), as well as the Agatston Research Institute (ARI); a non-profit foundation; is Principal Investigator or Co-Principal Investigator on investigator-initiated research grants funded by Bayer to FAU and ARI, as well as Kraft to ARI; is a consultant, including as Chair or Member on Data and Safety Monitoring Boards, for AstraZeneca, Bayer, Bristol-Myers Squibb, Chattem, Delaco, Food and Drug Administration, GlaxoSmithKline, McNeil, National Institutes of Health, Novartis, Pfizer, Reliant, TAP, and UpToDate; and receives royalties for authorship or editorship of three textbooks and royalties as coinventor on patents concerning inflammatory markers and cardiovascular disease which are held by Brigham & Women’s Hospital. Dr Schror receives project support from AstraZeneca and Schering. He consults for AstraZeneca, Bayer, Boehringer Ingelheim, BraunMelsungen, and Schering. Dr Weisman is a consultant for Bayer, GlaxoSmithKline, Roche, Boehringer Ingelheim, and Chatten. Dr FitzGerald receives current project support from the National Institutes of Health, GlaxoSmithKline, Merck, Servier, and Boehringer Ingelheim. He consults for Bayer, Merck, Novartis, Pfizer, Lilly, CV Therapeutics, Boehringer Ingelheim, and Roche.